Skip to content
Screener

CorMedix CRMD Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$127.4MBeat by $22.4M
EPS$0.43Beat by $0.08
Revenue estimate$105.0M
EPS estimate$0.35

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$53.3M
EPS estimate-$0.10

Financials

Q1 2026

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$536.75M+33.7%
P/E3.2×—
P/S1.3×-3.5×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin41.9%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity60.7%—
Current ratio3×-1.2×

Segments

By product

See full
DefenCath$97.5M+150%
Melinta Portfolio$24.4M—
Contract revenue$5.5M—

FAQ

When did CorMedix report Q1 2026 earnings?
CorMedix (CRMD) reported Q1 2026 earnings on May 14, 2026 before market open.
What were CorMedix's Q1 2026 revenue and EPS?
CorMedix reported revenue of $127.4M and eps of $0.43 for Q1 2026.
Did CorMedix beat estimates in Q1 2026?
Revenue beat the consensus estimate of $105.0M by $22.4M. EPS beat the consensus estimate of $0.35 by $0.08.
How did CorMedix's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 226.0% from $39.1M a year earlier and eps grew 43.3% from $0.30.
Where can I find CorMedix's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001410098-26-000020) and the 10-Q periodic report (0001410098-26-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.